Jefferies Sees Upside to Stemline Therapeutics (STML) SL-401 Timeline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall Street ends choppy session lower as tech shares drop
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
- Oil prices fall 1% to 4-month lows as progress in US-Iran talks cools supply concerns
- Trump discloses over $1.4 billion in crypto income in 2025 filing
Aegis Capital Adjusts PT on Stemline (STML) to $55 Following Financing, Development Update
January 30, 2015 9:49 AM ESTAegis Capital lowers its price target on Stemline Therapeutics (Nasdaq: STML) from $68 to $55 and maintains a Buy rating on the stock following a recent financing round and development update.
Analyst Yi Chen commented, Stemline Therapeutics recently announced that it had licensed from... More
Stemline Therapeutics' (STML) SL-701 Receives FDA Orphan Designation as Glioma Treatment
January 30, 2015 8:43 AM ESTStemline Therapeutics (NASDAQ: STML) announced that SL-701 has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of glioma.
SL-701 is an enhanced immunotherapy designed to activate the immune system to kill malignant gliomas, which are aggressive malignancies of the brain that... More
